Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes
- Departments of Molecular and Medical Pharmacology and Internal Medicine (Endocrinology), David Geffen School of Medicine at UCLA, University of California at Los Angeles, Los Angeles, California, USA
- Correspondence to:
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 LeConte Ave, 23-120 CHS, Box 173517, Los Angeles, CA 90095-1735;
- Accepted 21 July 2006
- Published Online First 29 August 2006
Objective: To determine the effect of plasma glucose lowering on coronary circulatory function in type 2 diabetes mellitus.
Methods: Twenty patients with type 2 diabetes and 18 weight-matched controls were studied. At baseline, myocardial blood flow (MBF) was measured with [13N]ammonia and positron emission tomography at rest, during cold pressor testing (CPT), and during adenosine hyperaemia. In diabetic patients, MBF and blood chemistry were analysed again after 3 months of glucose-lowering treatment with glyburide and metformin.
Results: Although hyperaemic MBF did not differ significantly between the patients and controls (1.81 (0.38) v 1.97 (0.43) ml/min/g; mean (SD)), the CPT-induced MBF increase (ΔMBF) was significantly less in diabetic patients than in controls (0.07 (0.07) v 0.25 (0.12) ml/min/g; p<0.001). Treatment with glyburide and metformin significantly decreased plasma glucose concentrations from 207 (76) to 134 (52) mg/dl (p<0.001). This decrease in plasma glucose was paralleled by a significant increase in ΔMBF in response to CPT (0.20 (0.16) from 0.07 (0.07) ml/min/g; p<0.001), which tended to be lower than in controls at baseline (0.20 (0.16) v 0.25 (0.12) ml/min/g; p = NS). The decrease in plasma glucose concentrations correlated significantly with the improvement in ΔMBF in response to CPT (r = 0.67, p<0.01).
Conclusions: Type 2 diabetes mellitus is associated with abnormal MBF response to CPT, which can be significantly improved by euglycaemic control with glyburide and metformin. The close association between the decrease in plasma glucose concentration and the improvement in coronary vasomotor function in response to CPT suggests a direct adverse effect of raised plasma glucose concentration on diabetes-related coronary vascular disease.
- CPT, cold pressor testing
- LDL, low-density lipoprotein
- MBF, myocardial blood flow
- RPP, rate–pressure product
- coronary disease
- cold pressor testing
- type 2 diabetes
- myocardial blood flow
- positron emission tomography
Published Online First 29 August 2006
↵* These authors contributed equally.
Financial support: Supported in part by Research Grant HL 33177, National Heart, Lung and Blood Institute, Bethesda, MD, USA.
Competing interests: None.
The study was approved by the UCLA Institutional Review Board.